Fig. 1.
CDR3 fragment analysis of (A) TCR AV 12S1 CD4 T-cell expansion (49%) with AV 12S1 CD4 control and of (B) BV3 CD8 expansion (33%) with BV3 CD8 control of patient 1.
CDR3 fragment analysis of (A) TCR AV 12S1 CD4 T-cell expansion (49%) with AV 12S1 CD4 control and of (B) BV3 CD8 expansion (33%) with BV3 CD8 control of patient 1.
